Pharmacological Treatment of Panic Disorders

  • James C. Ballenger


Effective pharmacotherapy of panic disorder and agoraphobia with panic attacks was introduced during the early 1960s, when almost simultaneously it was reported that both monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) reduced symptoms of panic and phobic avoidance. This chapter reviews the accumulated evidence regarding the effective pharmacotherapy of these disorders.1


Panic Disorder Panic Attack Monoamine Oxidase Inhibitor Mitral Valve Prolapse Phobic Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ballenger JC. Pharmacotherapy of the panic disorders. J Clin Psychiatry 1987;47(6):27–32.Google Scholar
  2. 2.
    Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964; 53: 397–408.CrossRefGoogle Scholar
  3. 3.
    Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962; 119: 432–438.PubMedGoogle Scholar
  4. 4.
    Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63–72.PubMedGoogle Scholar
  5. 5.
    Zitrin CM, Klein DF, Woerner MG, et al. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125–138.PubMedGoogle Scholar
  6. 6.
    Ballenger JC, Sheehan DV, Jacobsen G. Antidepressant treatment of severe phobic anxiety. In: Abstracts of the Scientific Proceedings of the 130th Annual Meeting of the American Psychiatric Association, Toronto, 1977.Google Scholar
  7. 7.
    Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51–59.PubMedGoogle Scholar
  8. 8.
    Marks IM, Gray S, Cohen D, et al. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry 1983; 40: 153–162.PubMedGoogle Scholar
  9. 9.
    McNair DM, Kahn RJ. Imipramine compared with a benzodiazepine for agoraphobia. In Klein DF, Rabkin JG (eds): Anxiety: New Research and Changing Concepts. New York: Raven Press, 1981.Google Scholar
  10. 10.
    Mavissakalian M, Michelson L. Agorphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings. Psychopharmacol Bull 1982; 18: 91–103.PubMedGoogle Scholar
  11. 11.
    Ballenger JC, Peterson GA, Laraia M, et al. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In Ballenger JC (ed): Biology of Agoraphobia. Washington, DC: APA Press, 1984.Google Scholar
  12. 12.
    Mavissakalian M, Michelson L, Dealy RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 1983; 143: 348–355.PubMedCrossRefGoogle Scholar
  13. 13.
    Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affective Disord1987; 13: 153–168.CrossRefGoogle Scholar
  14. 14.
    Zitrin CM, Klein DF, Woerner MG. Behavioral therapy, supportive psychotherapy, imipramine, and phobias. Arch Gen Psychiatry 1978; 35: 307–316.PubMedGoogle Scholar
  15. 15.
    Colgan A. A pilot study of Anafranil in the treatment of phobic states. Scott Med J 1975; 20 (Suppl 1): 55–60.PubMedGoogle Scholar
  16. 16.
    Waxman D. An investigation into the use of Anafranil in phobic and obsessional disorders. Scott Med J 1975; 20 (Suppl 1): 61–66.PubMedGoogle Scholar
  17. 17.
    Carey MS, Hawkinson R, Kornhaber A, et al. The use of clomipramine in phobic patients: preliminary research report. Curr Ther Res 1975; 17: 107–110.PubMedGoogle Scholar
  18. 18.
    Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res 1977; 5: 116–123.PubMedGoogle Scholar
  19. 19.
    Gloger S, Grunhaus L, Birmacher B, et al. Treatment of spontaneous panic attacks with chlorimipramine. Am J Psychiatry 1981; 138: 1215–1217.PubMedGoogle Scholar
  20. 20.
    Grunhaus L, Gloger S, Birmacher B. Chlorimipramine for panic attacks in patients with mitral valve prolapse. J Clin Psychiatry 1984; 45: 25–27.PubMedGoogle Scholar
  21. 21.
    Escobar JI, Landbloom RP. Treatment of phobic neurosis with chlorimipramine: a controlled clinical trial. Curr Ther Res 1976; 20: 680–685.PubMedGoogle Scholar
  22. 22.
    Karabanow O. Double-blind controlled study in phobias and obsessions. J Int Med Res 1977; 5: 42–48.PubMedGoogle Scholar
  23. 23.
    Amin MM, Ban TA, Pecknold JC, et al. Chlorimipramine (Anafranil) and behavior therapy in obsessive-compulsive and phobic disorders. J Int Med Res 1977; 5: 33–37.PubMedGoogle Scholar
  24. 24.
    Lydiard RB. Desipramine in panic disorder: an open, fixed-dose study. Presented at the Annual Meeting of the American Academy of Clinical Psychiatry, San Francisco, 1985.Google Scholar
  25. 25.
    Rifkin A, Klein DF, Dillon D, et al. Blockade by imipramine or desipramine of panic induced by sodium lactate. Am J Psychiatry 1981; 138: 676–677.PubMedGoogle Scholar
  26. 26.
    Muskin PR, Fyer AJ. Treatment of panic disorder. J. Clin Psychopharmacol 1981; 1: 81–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Sheehan DV. Current views on the treatment of panic and phobic disorders. Drug Ther 1982; 12: 74–93.Google Scholar
  28. 28.
    Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (Bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983; 3: 28–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973; 32: 237–254.PubMedCrossRefGoogle Scholar
  30. 30.
    Solyom L, Heseltine GFD, McClure DJ, et al. Behavior therapy versus drug therapy in the treatment of phobic neuroses. Can Psychiatr Assoc J 1973; 18: 25–32.PubMedGoogle Scholar
  31. 31.
    Mountjoy CQ, Roth M, Garside RF, et al. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. Br J Psychiatry 1977; 131: 486–492.PubMedCrossRefGoogle Scholar
  32. 32.
    Solyom C, Solyom L, LaPierre Y, et al. Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 1981; 16: 239–247.PubMedGoogle Scholar
  33. 33.
    Lipsedge MS, Hajioff J, Huggins P, et al. The management of severe agoraphobia: a comparison of iproniazid and systematic desensitization. Psychopharmacologia 1973; 32: 67–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Kelly D, Guirguis W, Frommer E, et al. Treatment of phobic states with antidepressants: a retrospective study of 246 patients. Br J Psychiatry 1970; 116: 387–398.PubMedCrossRefGoogle Scholar
  35. 35.
    Chouinard G, Annable L, Fontaine R, et al. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind, placebo-controlled study. Psychopharmacology 1982; 77: 229–233.PubMedCrossRefGoogle Scholar
  36. 36.
    Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984; 4: 66–75.PubMedCrossRefGoogle Scholar
  37. 37.
    Alexander DE, Alexander DD. Alprazolam treatment for panic disorders. Presented at the 137th Annual Meeting of the American Psychiatric Association, Los Angeles, 1984.Google Scholar
  38. 38.
    Ballenger JC, Burrows G, DuPont RL Jr, Lesser JM, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45 (5): 413–422.PubMedGoogle Scholar
  39. 39.
    Noyes R Jr, DuPont RL Jr, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry 1988; 45 (5): 423–428.PubMedGoogle Scholar
  40. 40.
    Noyes R, Anderson D, Clancy J. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41: 287–292.PubMedGoogle Scholar
  41. 41.
    Mavissakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose-response relationship. Am J Psychiatry 1985; 142: 1032–1036.PubMedGoogle Scholar
  42. 42.
    Mavissakalian M, Perel JM, Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J Clin Psychopharmacol 1984; 4: 36–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • James C. Ballenger

There are no affiliations available

Personalised recommendations